跳到正文
原文
MedPage Today·· 2 天前AI 评分60

ESMO 专家圆桌讨论:围手术期免疫治疗在膀胱癌中的争议与选择

Trials Raise Questions About Perioperative Immunotherapy in Bladder Cancer

AI 导读

MedPage Today 邀请三位膀胱癌专家就 ESMO congress 上公布的三项围手术期临床试验进行讨论。KEYNOTE-866 和 ENERGIZE 两项 III 期研究结果为阴性——病理完全缓解率有所提高,但事件无进展生存期和总生存期未见改善;此前阳性的 NIAGARA 试验则在各项终点上均显示获益。

正文

— Experts weigh negative KEYNOTE-866 and ENERGIZE findings against positive NIAGARA trial

by Gregory Laub, Senior Director, Video, MedPage Today

November 17, 2026 • 4 min read

In this exclusive roundtable video from MedPage Today, three expert leaders in the field of bladder cancer discuss the latest research presented at the European Society for Medical Oncology (ESMO) congress.

Moderator Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai in New York City, is joined by David Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and Stephanie Berg, DO, of the Dana-Farber Cancer Institute in Boston.

In this second of four episodes, they examine the disappointing results from the KEYNOTE-866 and ENERGIZE trials, how those findings compare with the positive NIAGARA trial, and what they mean for perioperative treatment decisions in muscle-invasive bladder cancer.

Click here to watch all episodes of this roundtable series.

Following is a transcript of their remarks:

Galsky: Okay, so let's talk a little bit about the next set of studies. And we saw two studies at ESMO, really along the same theme, and that is should we add immune checkpoint blockade to cisplatin-based therapy for cisplatin-eligible patients with muscle-invasive bladder cancer? We saw the results from KEYNOTE-866 and the ENERGIZE study, and I might add the long-awaited results from both of those studies. Previously, we saw the results of a similarly designed study called NIAGARA, which showed an improvement in essentially every endpoint, path CR [pathologic complete response] rate, event-free survival [EFS], and overall survival [OS].

But these studies were disappointing. There were some improvements in path CR rate versus the control arm. However, there was not an improvement in the time-to-event outcomes. And that raises some questions about cisplatin-based chemotherapy plus immune checkpoint blockade in the perioperative setting.

And now we have data with these different regimens that are mixing and matching components, so it's harder to say that it's just the class of IO [immunotherapy], PD-1 or PD-L1 blockade, or it's harder to say that it's the duration of treatment because duration of treatments were pretty similar. So, Dr. Berg, what do you make of these studies?

Berg: I agree. I kind of forgot they were around until when they were presented at ESMO. And I think ENERGIZE was really interesting because I didn't really know a lot about that compound. But in the end, they both were kind of negative and really aren't going to change practice in my mind.

But I think it was something where we saw, like you mentioned, some path CR gains, but it's also with the design of the studies and what's going to actually happen in current practice compared to what we were just discussing within ADC [antibody-drug conjugate] and IO. I'm not sure they're not going to really change practice, but it was something that, again, they were finally out and we are definitely abandoning cisplatin chemo.

Galsky: So these studies might not change practice themselves, as you point out, but there is another study that showed benefit with this type of approach, which is NIAGARA. And that really makes one wonder if all three studies were presented at the same time, whether or not the general interpretation of the studies would be different than having the positive study come out first and well before the others.

So, Dr. Aggen, what do these studies tell you in terms of how to interpret NIAGARA in retrospect?

Aggen: I think you can't compare because these trials sort of happen in different eras. Perhaps in the control arm of the more contemporary studies like ENERGIZE, there was more use of adjuvant IO that may have narrowed the difference. It's also quite striking in ENERGIZE, it enrolled a very high percentage of patients who had clinical T2 disease. And so maybe it was a slightly lower-risk population as well.

I think the question though is sort of obsolete given the striking results from KEYNOTE-905, KEYNOTE-B15, and now VOLGA that say that you should probably be giving ADC-IO to patients. I think that there may be a small subgroup with either variant histologies or other tumor features that needs durvalumab [Imfinzi] in combination with cisplatin. We don't really have the granularity of who that is.

And so at the moment I still think ADC-IO is our backbone of perioperative therapy. It is an interesting academic question though that you have two phase III trials with chemo-IO that show perhaps higher path CR rates than NIAGARA, but not the same benefit in terms of EFS and OS. And I don't think we're going to get crystal answers as to why those differences exist.

Galsky: So, Dr. Berg, Monday morning, any patient walking in the door who is going to be an appropriate candidate for cisplatin-based chemotherapy plus immune checkpoint blockade versus EV [enfortumab vedotin (Padcev)] plus immune checkpoint blockade?

Berg: I do agree with Dr. Aggen. I think the non-bladder or non-urothelial histology, perhaps even upper tract urethra, since they weren't enrolled on these studies, you would really discuss about cisplatin perioperative therapy. Even though those other studies too with variant histology, we normally go right to cystectomy.

But again, we can consider a perioperative therapy for them and I think it's still appropriate and active in those subsets, but I think more is going to come out with ADC and the non-urothelial histology. So there's some work being done in that center, but I think that's what I would use right now. I would still consider it pretty appropriate.

Galsky: Thank you.

来源:MedPage Today · medpagetoday.com